XENETIC BIOSCIENCES INC (XBIO)
US9840156023 - Common Stock
XBIO Stock Earnings: Xenetic Biosciences Beats EPS, Misses Revenue for Q4 2023
XBIO stock results show that Xenetic Biosciences beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.
XBIO Stock Earnings: Xenetic Biosciences Beats EPS, Misses Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Xenetic Biosciences (NASDAQ:XBIO) just reported results for the fourth quarter ...
Xenetic Biosciences announces reverse stock split of common stock (NASDAQ:XBIO)
Xenetic Biosciences (XBIO) has announced it will effect a one-for-ten reverse stock split of its outstanding common stock, effective May 15, 2023.The company expects that upon the...
Xenetic Biosciences, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update
Second quarter marked by deal to in-license DNase-based oncology platform which expands pipeline with well-defined and accelerated path to clinic
Xenetic Biosciences, Inc. and VolitionRx Limited Collaborate to Develop NETs-Targeted Adoptive Cell Therapies for the Treatment of Cancer
FRAMINGHAM, MA / ACCESSWIRE / August 2, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard-to-treat cancers, and VolitionRx Limited (NYSE AMERICAN:VNRX) ("Volition"), a multi-national epigenetics company, today announced a research and development collaboration to develop Neutrophil Extracellular Traps ("NETs") targeted, adoptive cell therapies for the treatment of cancer.
Xenetic Biosciences, Inc. Engages Catalent for Clinical Manufacturing to Advance DNase-Based Oncology Platform Towards Phase 1 Study
FRAMINGHAM, MA / ACCESSWIRE / July 7, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard-to-treat cancers, today announced it has entered into a manufacturing agreement with Catalent Pharma Solutions LLC ("Catalent"), which will include cGMP manufacturing for the Company's recombinant protein, Human DNase I.
JTC Team to Host Virtual Investor Innovation in Oncology Featuring Xenetic Biosciences
- Live video webcast with moderated roundtable with members of the Xenetic leadership team and surgical oncology Key Opinion Leader, Allan Tsung, MD on Thursday, June 9th at 11:00 AM ET -
Xenetic Biosciences, Inc. to Participate in the Virtual Investor Innovation in Oncology Event
Live Video Webcast With Moderated Roundtable With Members of the Xenetic Leadership Team and Surgical Oncology Key Opinion Leader, Allan Tsung, MD on Thursday, June 9th at 11:00 AM ET
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright Global Investment Conference
Live Webcast Presentation on Wednesday, May 25th at 4:00 PM ET FRAMINGHAM, MA / ACCESSWIRE / May 18, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies for the treatment of hard to treat cancers, today announced that Jeffrey F. Eisenberg, Chief Executive Officer of Xenetic, will present at the H.C. Wainwright Global Investment
Xenetic Biosciences, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update
- Company completed recent transaction to expand oncology pipeline with in-licensing of DNase based platform comprising multiple therapeutic modalities - DNase based oncology platform has the potential to improve outcomes of existing therapeutic agents in multiple solid tumor indications - Focusing resources on advancing DNase based oncology platform in locally advanced or metastatic solid tumors towards Phase 1 clinical development - Ended
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Good morning! We're gearing up for another busy day of trading with a breakdown of the biggest pre-market stock movers for Thursday!